Malladi Drugs & Pharmaceuticals Limited, Unit-I – FDA 483, Nov 11, 2022

The Food and Drug Administration (FDA) conducted an inspection of the firm identified as "meena" on or around November 11, 2022. This inspection resulted in the issuance of an FDA Form 483, outlining two significant observations related to the company's quality control and process validation practices. The first observation noted that sampling plans and procedures for finished products were not based on scientifically sound practices. Specifically, records for finished product release did not accurately reflect the actual sampling, as empty containers were observed being labeled as sampled, leading to discrepancies in documentation. The second observation highlighted deficiencies in the firm's written validation protocols. During a review of validation for in-process control laboratory equipment, it was found that the loaded cycle study did not include items routinely sterilized, such as empty 1-liter and 2-liter flasks, and the number of filled flasks used in another study was not specified in the protocol or report. These findings suggest potential deviations from regulatory expectations, such as Good Manufacturing Practices. The firm is required to evaluate these observations, develop and implement appropriate corrective actions, and submit a formal response to the FDA addressing how these issues will be resolved to ensure compliance.